Geniculate Artery Embolization for Osteoarthritis

NCT ID: NCT04456569

Last Updated: 2025-06-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-01
• Study Completion Date: 2026-02-01

Brief Summary

The need for exploration of more definitive and cost effective non-arthroplasty treatments of osteoarthritis (OA) has been demonstrated by the orthopedic and health economic research.

Embolotherapy of neovessels associated with OA joints has been shown to be promising in patients with knee OA. There is a need for level one evidence drawn from randomized clinical trials to prove the safety, feasibility and efficacy of knee embolotherapy compared to standard of care.

This randomized pilot study will assign 10 patients with mild-moderate OA to undergo geniculate artery embolization plus standard of care (defined in this study as: physical therapy and oral anti-inflammatory medications, with a maximum of 1 joint injection at the time of enrollment) and 10 patients to receive only medical standard of care (also having had a maximum of 1 joint injection prior to enrollment). The goal of this pilot study is to obtain preliminary estimates of safety and efficacy of embolotherapy to provide sustained symptom control and modify disease progression in patients with mild to moderate knee OA.

Detailed Description

This is a single center, two-arm, open label, pilot study to assess feasibility and safety and obtain a preliminary estimate of efficacy of geniculate artery embolization in reducing pain compared to a control group undergoing conservative presurgical management. The 20 patients will be randomly divided into two groups of 10 in 1:1 allocation. One group will have embolization of the geniculate artery branches and standard of care while the other will have only the standard care. Following the completion of the 10 participants in each arm, a safety and data review will be undertaken (Visit 4 in the GAE group and Visit 2 of the SOC). The data will be assessed regarding the trends between the groups as they relate to KOOS/WOMAC pain scale, MRI / Xray evaluation of OA, and presence of inflammatory biomarkers.

Conditions

Osteo Arthritis Knee; Arthritis; Osteoarthritis; Osteoarthritis, Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

GAE + Standard of Care

Participants in this arm will receive geniculate artery embolization and standard of care.

Group Type: EXPERIMENTAL

Geniculate Artery Embolization

Intervention Type: DEVICE

All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.

Standard of Care

Participants in this arm will receive standard of care only.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Geniculate Artery Embolization

All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Between 40 - 70 years of age.
• Unilaterally dominant symptomatic OA (bilateral radiographic OA will not exclude).
• Symptomatically refractory of at least 3 months of medical and/or rehabilitation measures (anti-inflammatory drugs, and/or physical therapy, and/or strength conditioning, and/or intra-articular injections of the affected knee in the last 3 months).
• Kellgren-Lawrence grade 1, 2, or 3 on radiograph of the knee
• Willing to comply with the protocol requirements and willing to undergo non- contrast MRI during screening and at 12 months.
• Willing to comply with regular follow up during the 12 month follow-up period.
• Not a current candidate for partial or total knee arthroplasty.
• WOMAC Score >=6 in at least 2 categories.

Exclusion Criteria

• BMI >35 kg/m2
• Advanced peripheral arterial disease (resting ABI <= 0.9).
• Known significant peripheral arterial disease precluding common femoral catheterization
• Have smoked tobacco regularly (smoking 1 or more tobacco product(s) per week) within the last year
• Diabetics with hemoglobin A1C of >9%
• Previous lower extremity embolization
• Uncontrolled emotional disorders per patient medical history
• Chronic pain syndrome or currently under a pain contract.
• Anatomic variants involving the lower extremities which would increase the risk of non-target embolization
• Renal insufficiency based on an estimated GFR<45 ml/min who are not already on hemodialysis.
• Abnormal INR (>1.5)
• Platelet count <50x109/L.
• Currently receiving medications for anticoagulation which cannot safely be held for the procedure and for 7 days post-procedure.
• Known severe allergy to iodine which cannot be adequately pre-medicated
• Pregnant or intend to become pregnant within 6 months of the procedure
• Contraindication to drugs used for moderate sedation during interventional procedures, including Midazolam and Fentanyl
• Life expectancy <60 months
• Currently enrolled or who plan to enroll in other investigations that conflict with follow-up testing or confounds data in this trial
• Contraindications to medical and physical rehabilitative treatments of OA.
• Advanced atherosclerosis.
• Current or previous lower extremity fistula.
• Rheumatoid arthritis or seronegative arthropathies.
• WOMAC Pain Scale < 6
• Steroid injection in the affected joint within 3 months of screening. I- n investigator assessment, patient is not a candidate for study participation

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Reza Talaie, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Research Coordinator

Role: CONTACT

SurgCTO@umn.edu

612-624-7463

Facility Contacts

Reza Talaie, MD

Role: primary

Other Identifiers

RAD-2019-27368

Identifier Type: -

Identifier Source: org_study_id